HEALTH AND SAFETY

» Drug, Devices, and Supplements

» Physician Accountability

» Consumer Product Safety

» Worker Safety

» Health Care Delivery

» Auto and Truck Safety

» Global Access to Medicines

» Infant Formula Marketing

 

More Information on Ethics and Clinical Trials

More information on surfactant (Surfaxin)

Description of Efforts to Redesign Surfactant (Surfaxin) Study in Latin America

February 17, 2007

In 2001, Public Citizen criticized a proposed study by the United States drug company Discovery Laboratories. The study would have explored the effectiveness of Discovery's drug Surfaxin in the treatment of Respiratory Distress Syndrome, a sometimes-fatal disease of premature infants, in four Latin American countries. Although four similar surfactant drugs were already approved in the United States and had been shown to reduce mortality rates by about one-third, the company proposed giving half of the patients a placebo (sham treatment), reasoning that in those countries people did not receive surfactant anyway. Public Citizen mounted an ultimately successful campaign against the trial. In 2007, we published a book chapter describing the circumstances surrounding this trial:

Lurie P, Wolfe SM. The developing world as the "answer" to the dreams of pharmaceutical companies: the Surfaxin story. In: Lavery JV, Grady C, Wahl ER, Emanuel EJ. Ethical Issues in International Biomedical Research. Oxford University Press, Oxford, 2007, pp. 159-70.

The chapter is available as a pdf

Copyright © 2014 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.

 

To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.